Tizoxanide-d4
(Synonyms: 替唑尼特 D4) 目录号 : GC45580An internal standard for the quantification of tizoxanide
Cas No.:1246817-56-0
Sample solution is provided at 25 µL, 10mM.
Tizoxanide-d4 is intended for use as an internal standard for the quantification of tizoxanide by GC- or LC-MS. Tizoxanide is an active metabolite of the antiparasitic nitazoxanide .1 Tizoxanide is formed from nitazoxanide via deacetylation of nitazoxanide in the stomach. It is active against M. tuberculosis (MIC = 16 μg/ml). It also reduces the growth of the disease-causing parasites L. mexicana and T. cruzi in vitro (IC50s = 6.2 and 17.5 μM, respectively), inhibits influenza A replication (EC50s = 0.3-1 μM), and inhibits hepatitis B and hepatitis C virus replication (EC50 = 0.15 μM for both).2,3,4
References
1. de Carvalho, L.P.S., Lin, G., Jiang, X., et al. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J. Med. Chem. 52(19), 5789-5792 (2009).
2. Chan-Bacab, M.J., HernÁndez-NÚ•ez, E., and Navarrete-VÁzquez, G. Nitazoxanide, tizoxanide and a new analogue [4-nitro-N-(5-nitro-1,3-thiazol-2-yl)benzamide; NTB] inhibit the growth of kinetoplastid parasites (Trypanosoma cruzi and Leishmania mexicana) in vitro. J. Antimicrob. Chemother. 63(6), 1292-1293 (2009).
3. Rossignol, J.F., La Frazia, S., Chiappa, L., et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 284(43), 29798-29808 (2009).
4. Korba, B.E., Montero, A.B., Farrar, K., et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 77(1), 56-63 (2008).
Cas No. | 1246817-56-0 | SDF | |
别名 | 替唑尼特 D4 | ||
Canonical SMILES | OC1=C(C(NC2=NC=C([N+]([O-])=O)S2)=O)C([2H])=C([2H])C([2H])=C1[2H] | ||
分子式 | C10H3D4N3O4S | 分子量 | 269.3 |
溶解度 | DMSO : 25 mg/mL (92.84 mM; ultrasonic and warming and heat to 60°C); Ethanol : 1 mg/mL (3.71 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.7133 mL | 18.5667 mL | 37.1333 mL |
5 mM | 0.7427 mL | 3.7133 mL | 7.4267 mL |
10 mM | 0.3713 mL | 1.8567 mL | 3.7133 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet